Profile data is unavailable for this security.
About the company
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
- Revenue in USD (TTM)13.85bn
- Net income in USD4.65bn
- Incorporated1988
- Employees13.45k
- LocationRegeneron Pharmaceuticals Inc777 Old Saw Mill River RoadTARRYTOWN 10591United StatesUSA
- Phone+1 (781) 370-5000
- Websitehttps://www.regeneron.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICON PLC | 8.31bn | 747.89m | 16.81bn | 42.25k | 22.64 | 1.72 | 13.04 | 2.02 | 8.99 | 8.99 | 99.87 | 118.39 | 0.4852 | -- | 2.99 | 202,112.50 | 4.37 | 3.93 | 5.24 | 4.80 | 29.65 | 28.91 | 9.00 | 7.37 | -- | 4.41 | 0.2599 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
| Iqvia Holdings Inc | 15.32bn | 1.41bn | 35.30bn | 88.00k | 25.50 | 5.07 | 13.91 | 2.30 | 7.62 | 7.62 | 83.09 | 38.36 | 0.5762 | -- | 4.77 | 176,034.50 | 5.31 | 3.24 | 7.13 | 4.07 | 35.17 | 34.32 | 9.21 | 6.03 | -- | 3.43 | 0.6598 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
| Regeneron Pharmaceuticals Inc | 13.85bn | 4.65bn | 81.69bn | 13.45k | 18.39 | 2.79 | 15.94 | 5.90 | 40.42 | 40.42 | 120.30 | 266.36 | 0.3979 | 0.6523 | 2.37 | 1,029,524.00 | 13.37 | 20.18 | 14.93 | 23.22 | 86.86 | 87.66 | 33.61 | 38.11 | 4.46 | -- | 0.0844 | -- | 7.76 | 14.34 | -8.87 | 10.72 | 19.32 | -- |
| Vertex Pharmaceuticals Incorporated | 10.63bn | -479.80m | 116.20bn | 5.40k | -- | 7.44 | -- | 10.94 | -1.99 | -1.99 | 40.83 | 60.65 | 0.4834 | 1.67 | 6.46 | 1,967,741.00 | -2.18 | 19.92 | -2.64 | 23.64 | 86.12 | 87.67 | -4.52 | 35.85 | 2.20 | -- | 0.0072 | 0.00 | 10.51 | 26.49 | 8.96 | 46.50 | 22.02 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 9.67m | 8.92% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 8.85m | 8.16% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 5.69m | 5.25% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 5.50m | 5.08% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 4.90m | 4.52% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 4.30m | 3.97% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2024 | 3.35m | 3.09% |
| Dodge & Coxas of 30 Sep 2024 | 2.31m | 2.13% |
| Geode Capital Management LLCas of 30 Sep 2024 | 2.27m | 2.10% |
| Putnam Investment Management LLCas of 30 Sep 2024 | 1.41m | 1.30% |
